X lie f ol)O l,lt and public health. Most of rmedicales et de la sante ithearticles will be writ- publique. La plupart d ces ten, by invitation, by ack- articles auront tdoncee / nowkdged experts on the rediges sur demande par lesu subject. specialisteslesplusautorises.

Bulletin ofthe WorldHealth Organization, 62 (4): 509 -515 (1984) © World Health Organization 1984 Recent developments in the treatment of *

HUGH R. TAYLOR 1

The treatment ofonchocerciasis using andsuramin sodium, which can kill different stages oftheparasite, Onchocerca volvulus, remains unsatis- factory. Recent studies have more clearly defined the serious limitations ofthe exist- ingforms oftreatment. However, two new classes ofcompounds, the and , offer exciting new leads in the search for a safe and effective treatment that could be used on a large scale.

Onchocerciasis is a filarial infection that not only causes blindness and great suffering but also has far-reaching socioeconomic effects. It is possible to treat infected individuals on a case-by-case basis, but because of the serious side-effects associated with the currently available drugs, treatment is limited to persons with the most severe, sight-threatening disease or with acute, itching skin lesions.a The mass treatment of the millions of people infected with Onchocerca volvulus, many of whom are suffering from onchocerciasis, is unacceptable because of the high risks involved, even though all of them constitute a reservoir of the parasite. The two drugs for treating onchocerciasis, diethylcarbamazine and sodium, have been in use for more than three decades but only recently have their serious and long- lasting side-effects been understood. New drugs have now been synthesized and old compounds have been re-examined in an effort to find improved chemotherapeutic regimens. Much of this work has been stimulated and supported by the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. It is generally accepted that an ideal new drug should kill or permanently sterilize the adult worms of 0. volvulus without, at the same time, causing severe allergic reactions in the recipients from microfilaricidal action; it must also be safe under normal conditions of use, suitable for large-scale administration orally or intramuscularly, inexpensive, and effective in a single or small number of doses. * A French translation of this article will appear in a later issue of the Bulletin. Chairman, Steering Committee, Onchocerciasis Chemotherapy Project, World Health Organization; and Associate Professor, Dana Center for Preventive Ophthalmology, The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Requests for reprints should be sent to the Baltimore address. a Thepathogenesis and treatment ofocular onchocerciasis. Report of the eighth meeting of the Scientific Working Group on Filariasis, in collaboration with the programme for the prevention of blindness (unpublished WHO document TDR/FIL/SWG (8/82.3)). 4426 -509- 510 H. R. TAYLOR

The purpose of this paper is to review the various forms of treatment currently available, to highlight some of the latest information on the limitations of each, and to outline the clinical results obtained with some of the more recently tested compounds.

EXISTING TREATMENT METHODS

Nodulectomy The excision of onchocercal nodules (nodulectomy) is one of the earlier methods oftreat- ing onchocerciasis and has been widely used for more than 40 years in Mexico and Guat- emala, where head nodules are relatively common. Recently the efficacy of nodulectomy was critically examined in Africa. Albiez and co-workers found that, in similar geo- graphical areas with and without vector control, nodulectomy did not significantly alter microfilarial skin-snip counts when patients were examined two years after nodulectomy (1, 2). The lack of efficacy was probably because many adult female worms had not yet formed nodules at the time of surgery (3) and some nodules were so deep that they could not be palpated (4, 5). Nevertheless, many would argue that head nodules should be excised because of their proximity to the eye.

Diethylcarbamazine (DEC) Diethylcarbamazine, given as the citrate salt, has been the mainstay of treatment for onchocerciasis for many years.b There are, however, two major disadvantages to its use: one is the marked host response induced by the in vivo killing of microfilariae (6), and the other is the lack of effect on the adult worms (7), so that the therapeutic effect is only temporary. After DEC treatment, the skin is rapidly repopulated by new microfilariae over a period of some 6-12 months and the skin-snip counts usually return to pre-treatment levels within a year (8). DEC treatment of onchocerciasis is not without serious side-effects, however, and the Mazzotti reaction and other changes that occur with treatment can be very severe and greatly limit its usefulness (6, 9, 10). Of special importance are the recently recognized changes of optic neuritis, chorioretinitis, and proteinuria that occur with DEC treatment and which may be manifestations of tissue deposition of immune complexes (10-12). With respect to these complications, DEC treatment can be regarded as compressing ten years of disease into ten days of treatment. To compensate for the lack of an effect on adult worms, long-term suppressive doses of DEC have been advocated to keep the levels of microfilariae low (9, 13). The study by Sowa & Sowa was severely compromised by very poor compliance among the chidren they studied because of the persistence of side-effects (14); after five months of treatment, there was only a moderate decrease in microfilarial counts. The only reported study of long-term suppressive DEC treatment in adults, in which there was good compliance among the patients, showed that suppressive therapy was no more effective than a conventional course of DEC treatment (7). Even after six months of suppressive treatment, a continuing Mazzotti reaction occurred with each weekly dose. The number of intraocular microfil- ariae may have actually increased, and there were other complications perhaps related to high levels of circulating immune complexes (11). Of particular importance was the finding of new ocular lesions that developed during long-term DEC suppressive treatment (15). b HAWKING, F. Diethylcarbamazine: a review of the literature with special reference to its pharmacodynamics, toxicity and use in the therapy of onchocerciasis and otherfilarial infections. Unpublished document WHO/ONCHO/78. 142. TREATMENT OF ONCHOCERCIASIS 511

Another approach to lessen the side-effects of DEC treatment has been to reduce the dosage of DEC (16). Topical application of DEC lotion has been tried, but this has been shown to be both less effective and more dangerous than conventional DEC tablets (7, 17, 18). Very small doses of DEC (0.003-0.005 mg/kg/hour) have also been tried in preliminary studies to simulate continuous release (B. R. Jones, unpublished data, 1982). Even at these very low doses, all patients developed some features of the Mazzotti reaction which, although mild in many, were severe in a few. Further, despite clinical evidence that some microfilariae were killed, the microfilarial counts were not altered significantly. Even with doses that seem to be below the therapeutic range, the drug still induced serious reac- tions. Bearing in mind that the Mazzotti test uses only 50 mg of DEC and that Mazzotti reactions can be provoked within two hours of receiving as little as 12.5 mg (14), it is diffi- cult to envisage how even small doses of DEC can be effective in killing microfilariae without inducing a Mazzotti reaction, so that further studies on these lines are probably not warranted. In an attempt to block the Mazzotti reaction, many anti-inflammatory drugs have been studied (16). Although antihistamines and aspirin will ameliorate some of the symptoms and steroids will significantly suppress the Mazzotti reaction, none of these drugs is capable of blocking the initiation of the reponse (9, 16, 19-21). It seems highly likely that the Mazzotti reaction is the clinical expression of a series, or possibly a cascade, of different immunological responses, including immediate hypersensitivity, complement activation, antibody-mediated microfilarial killing, and circulating immune complex deposition. Lodoxamide, a new drug that inhibits IgE-induced mediator release, can prevent the reac- tion provoked by DEC treatment in dogs infected with Dirofilaria immitis (22), but this drug has not yet been tested in human onchocerciasis.

Suramin sodium Suramin sodium, which kills both microfilariae and adult worms, is an inherently dangerous drug because of its high protein-binding affinity with alteration of function (23). The risk of optic neuropathy, nephrotoxicity, and the occasional death associated with suramin sodium treatment severely limits its usefulness, especially for mass treatment (24, 25). A recent three-year study in the Onchocerciasis Control Programme in the Volta river basin area showed that suramin, when used in a standard dosage, "was not beneficial...in certain cases it possibly even worsened the natural course of ocular onchocerciasis" (25). When used in a reduced dosage, suramin sodium appears to be safer and to have a lower frequency of side-effects, although at this dosage level it does not necessarily kill all the adult worms and is, therefore, also less effective (26). A compre- hensive review of the treatment of onchocerciasis with DEC and suramin has appeared recently.c

RECENTLY DEVELOPED COMPOUNDS

Benzimidazoles Benzimidazoles have an unusual effect on embryogenesis in various Onchocerca species. Their mechanism of action at the cellular level appears to be the disruption of microtubular formation which results in the cessation of the maturation of oocytes to the early morula c DUKE, B. 0. L. ET AL. Current views on the treatment of onchocerciasis with diethylcarbamazine citrate and suramin. Unpublished document WHO/ONCHO/81.156. 512 H. R. TAYLOR stage (27-29). Thus, their main mechanism of action is quite different from that of the other drugs used against 0. volvulus. In general, they do not kill microfilariae and, therefore, they do not initiate the cascade of events leading to a Mazzotti reaction. Instead, they appear to "sterilize" the adult females, at least temporarily, and allow a gradual attrition in the numbers of microfilariae; as the existing microfilariae die, they are not replaced (30,31). However, drugs of this group are very poorly absorbed orally (27,32,33) and, when used in conventional dosages, have been ineffective against 0. volvulus (34-38). The use of much larger doses is therefore necessary. is the most widely tested . When used in large dosages (30-50 mg/kg/day for 2 to 4 weeks), it has a significant effect on embryogenesis at two months; and it produces a prolonged reduction in microfilarial skin-snip counts that may persist for up to one year (30, 31). However, further studies have suggested that the effect on embryogenesis may be temporary and last for only 3-6 months (39). Mebendazole has also been used in combination with . Levamisole itself does not reduce micro- filarial counts or affect the adult worms (30, 36, 40,41). Studies in Mexico have not shown any advantage in the combined therapy of mebendazole and levamisole (30), whereas two studies from Africa suggest that combined treatment may possibly be more effective than mebendazole alone in some regimens, although this difference is not consistent (39, and 0. 0. Kale, unpublished data, 1982). Mebendazole, however, has three serious disadvantages when used at the prolonged high-dose level needed for treating onchocerciasis. The first and most serious is that it is teratogenic in some experimental animals (42) and, therefore, is highly unlikely to be acceptable for general use, especially for the treatment of women. Secondly, idiosyncratic neutropenia can develop with mebendazole treatment, and death from septicaemia has been reported in a patient receiving high doses of mebendazole for the treatment of hydatid disease (43). Finally, the drug also seems to have a moderate microfilaricidal effect and produces a mild Mazzotti type of reaction with its attendant problems (30). is a more recently developed benzimidazole agent. Although effective against a range of intestinal parasites when given orally, it is even less well absorbed than mebendazole (27,33, 44, 45). In cattle, a microfined preparation of flubendazole was well absorbed and had a profound effect on embryogenesis of 0. gibsoni and 0. gutturosa (D. B. Copeman, personal communication, 1982). In man, flubendazole has been tested by intramuscular injection, 750 mg once a week for five injections (29). The formulation used produced marked local reactions but, apart from severe pain and inflammation at the injection site, treatment with flubendazole was essentially without side-effects. In particular, it did not produce any demonstrable microfilaricidal side-effects, and it totally blocked normal embryogenesis in female worms as shown on examination two months after treatment. Its effect on embryogenesis and skin counts was more marked than that of mebendazole, as judged by retrospective comparison (30). Flubendazole does not have the disadvantages of mebendazole in that it does not appear to be microfilaricidal or teratogenic and it is not known to cause neutropenia, although very few patients have been treated thus far. It is, however, very expensive. The duration of the effect of flubendazole on the embryogenesis of 0. volvulus is unknown and must be determined. If it were possible to enhance the oral absorption of flubendazole, e.g., by the use of an appropriate microfined formulation, or if it were possible to prepare a formu- lation for intramuscular injection without resulting pain, then flubendazole would appear to be a most promising drug for the treatment of onchocerciasis. It has obvious advantages over DEC and other microfilaricidal drugs; and, although it "sterilizes" rather than kills the adult worms, it is inherently much safer than suramin sodium. TREATMENT OF ONCHOCERCIASIS 513

Ivermectin A recent study in lightly infected patients showed that , an , reduced microfilarial skin-snip counts and its use was not accompanied by a Mazzotti reaction (46). Ivermectin is therefore a most interesting drug, particularly as it seems to be effective in a single oral dose. However, the optimal dosage has yet to be determined. Closely standardized clinical studies are now being conducted to evaluate the safety and efficacy of ivermectin in patients who are moderately or heavily infected with 0. volvulus in order to assess the effect of this drug on ocular changes, and to compare it with DEC on a double-blind basis with respect to production of the Mazzotti reaction. The results of these studies are eagerly awaited because from current knowledge of filaricides, it seems likely that any drug which kills microfilariae will also induce a Mazzotti reaction in some degree. Only if ivermectin is an exception in this respect can it offer significant advantages over DEC. Otherwise it could turn out to be similar to , which does reduce micro- filarial skin-snip counts (although no more effectively than DEC) and also produces a Mazzotti type of reaction (13, 47-50). Of further interest, and of considerable importance, is the preliminary finding that iver- mectin may act as a chemoprophylactic for 0. gibsoni infection in cattle (D. B. Copeman, personal communication, 1982). At present, no other compound is known to prevent the development of the larval stages of any Onchocerca species, and a drug with this action could be of considerable use in controlling the transmission of human onchocerciasis.

REFERENCES

1. ALBIEZ, E. J. ET AL. Assessment of onchocerciasis two years after nodulectomy in a region with interrupted transmission. Zentralblattfur Bakteriologie, L Abt. Ref., 167: 313 (1980). 2. ALBIEZ, E. J. Microfilarial densities of Onchocerca volvulus in skin after a single nodulectomy in Liberia. Zentralblattfir Bakteriologie, L Abt. Ref., 167: 313 (1980). 3. COLLINS, R. C. ET AL. Early formation of the nodule in Guatemalan onchocerciasis. American journal of tropical medicine and hygiene, 31: 267-269 (1982). 4. ALBIEZ, E. J. Studies on nodules and adult Onchocerca volvulus during a nodulectomy trial in hyperendemic villages in Liberia and Upper Volta. I. Palpable and impalpable onchocercomata. Tropenmedizin und Parasitologie, 34: 54-60 (1983). 5. MEYERS, W. M. ET AL. Onchocerciasis: invasion of deep organs by Onchocerca volvulus. American journal of tropical medicine and hygiene, 26: 650-657 (1977). 6. MAZZOTTI, L. [Possibility of using the allergic reactions due to the administration of Hetrazan as an auxiliary diagnostic test for onchocerciasis]. Revista del Instituto de Salubridad y Enferme- dades Tropicales, 9: 235-237 (1948) (in Spanish). 7. TAYLOR, H. R. ET AL. Controlled of oral and topical diethylcarbamazine in treatment of onchocerciasis. Lancet, 1: 943-946 (1980). 8. DUKE, B. 0. The effects of drugs on Onchocerca volvulus. 1. Methods of assessment, population dynamics of the parasite, and the effects of diethylcarbamazine. Bulletin of the World Health Organization, 39: 137-146 (1968). 9. ANDERSON, J. ET AL. Effects of diethylcarbamazine on ocular onchocerciasis. Tropenmedizin und Parasitologie, 27: 263-278 (1976). 10. BIRD, A. C. ET AL. Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. British journal of ophthalmology, 64: 191-200 (1980). 11. GREENE, B. M. ET AL. Proteinuria associated with diethylcarbamazine treatment of oncho- cerciasis. Lancet, 1: 254-255 (1980). 514 H. R. TAYLOR

12. GREENE, B. M. ET AL. Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes. Journal of infectious diseases, 147: 890-897 (1983) 13. BELL, D. Treatment of onchocerciasis. British medicaljournal, 1: 1213 (1979). 14. SOWA, J. & SOWA, S. C. I. Long-term treatment of onchocerciasis in children with low doses of diethylcarbamazine. Annals of tropical medicine and parasitology, 72: 79-85 (1978). 15. TAYLOR, H. R. & GREENE, B. M. Ocular changes with oral and transepidermal diethyl- carbamazine therapy of onchocerciasis. British journal of ophthalmology, 65: 494-502 (1981). 16. JONES, B. R. Selected pharmaceutical developments required for prevention of massive blind- ness in developing countries. In: Institute of Medicine Conference Proceedings, Washington, DC, 1979. Washington, National Academy of Sciences, 1979, pp. 103-113. 17. TAYLOR, H. R. ET AL. Chemotherapy of onchocerciasis: a controlled clinical trial of topical diethylcarbamazine (DEC) in Guatemala. Tropenmedizin und Parasitologie, 31: 357-364 (1980). 18. HUTCHINSON, D. B. A. ET AL. Adverse reactions to cutaneous diethylcarbamazine in oncho- cerciasis. Lancet, 2: 46 (1979). 19. DUKE, B. 0. L. & ANDERSON, J. Onchocerciasis and its treatment. Tropical doctor, 2: 107-114 (1972). 20. AWADZI, K. ET AL. The chemotherapy of onchocerciasis. VI. The effect of indomethacin and on the Mazzotti reaction. Annals of tropical medicine and parasitology, 76: 323-330 (1982). 21. AWADZI, K. ET AL. The chemotherapy of onchocerciasis. VII. The effect of prednisone on the Mazzotti reaction. Annals of tropical medicine and parasitology, 76: 331-338 (1982). 22. DESOWITZ, R. S. ET AL. Inhibition of the adverse reaction of diethylcarbamazine in Dirofilaria immitis-infected dogs by lodoxamide ethyl. American journal oftropical medicine and hygiene, 31: 309-312 (1982). 23. HAWKING, F. Suramin: with special reference to onchocerciasis. Advances in pharmacology and chemotherapy, 15: 289-322 (1978). 24. ANDERSON, J. ET AL. Effects of suramin on ocular onchocerciasis. Tropenmedizin und Parasito- logie, 27: 279-296 (1976). 25. ROLLAND, A. ET AL. Review, after 3 years of the treatment with suramin, of a village suffering from onchocerciasis under entomological protection. Revue internationale du trachome, 57: 99-105 (1980). 26. ROUGEMONT, A. ET AL. Traitement de l'onchocercose par la suramine a faibles doses progressives dans les collectivites hyperendemiques d'Afrique occidentale. 1. Resultats parasitologiques et surveillance ophtalmologique en zone de transmission non interrompue. Bulletin of th'- World Health Organization, 58: 917-922 (1980). 27. VAN DEN BOSSCHE, H. A look at the mode of action of some old and new antifilarial compounds. Annales de la Societe Belge de Medecine Tropicale, 61: 287-296 (1981). 28. COPEMAN, D. B. An evaluation of the bovine-Onchocerca gibsoni, Onchocerca gutturosa model as a tertiary screen for drugs against Onchocerca volvulus in man. Tropenmedizin und Parasito- logie, 30: 469-474 (1979). 29. DOMINGUEZ-VASQUEZ, A. ET AL. Comparison of flubendazole and diethylcarbamazine in treat- ment of onchocerciasis. Lancet, 1: 139-143 (1983). 30. RIVAS-ALCALA, A. R. ET AL. 12 month follow-up of mebendazole therapy for onchocerciasis. Lancet, 2: 1043 (1981). 31. RIVAS-ALCALA, A. R. ET AL. Chemotherapy of onchocerciasis: a controlled comparison of mebendazole, levamisole, and diethylcarbamazine. Lancet, 2: 485-490 (1981). 32. BRUGMANS, J. P. ET AL. Mebendazole in enterobiasis: radiochemical and pilot clinical study in 1278 subjects. Journal of the American Medical Association, 217: 313-316 (1971). 33. SAIMOT, A. G. ET AL. Etude pharmacocinetique du flubendazole au cours de l'hydatidose humaine A E. granulosus. La nouvelle presse medicale, 10: 3121-3124 (1981). 34. DUKE, B. 0. L. & HAWKING, F. Trial of thiabendazole for the treatment of onchocerciasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 61: 273 (1967). 35. DUKE, B. 0. L. The effect of levamisole on Onchocerca volvulus. Transactions of the Royal Society of Tropical Medicine and Hygiene, 68: 71 (1974). TREATMENT OF ONCHOCERCIASIS 515

36. MAERTENS, K. & WERY, M. Effect of mebendazole and levamisole on Onchocerca volvulus and Dipetalonema perstans. Transactions of the Royal Society of Tropical Medicine and Hygiene, 69: 359-360 (1975). 37. JONES, B. R. ET AL. Evaluation of microfilaricidal effects in the cornea from topically applied drugs in ocular onchocerciasis: trials with levamisole and mebendazole. British journal of ophthalmology, 62: 440-444 (1978). 38. KALE, 0. Small-scale trials of six drugs against Onchocerca volvulus. Tropenmedizin und Parasitologie, 29: 163-167 (1978). 39. AWADZI, K. ET AL. The chemotherapy of onchocerciasis. VIII. Levamisole and its combination with benzimidazoles. Annals of tropical medicine and parasitology, 76: 459-473 (1982). 40. DUKE, B. 0. L. Further trial of levamisole against Onchocerca volvulus. Transactions of the Royal Society of Tropical Medicine and Hygiene, 69: 287-288 (1975). 41. PROD'HON, J. ET AL. Chimiotherapie de l'onchocercose. I. Essais de traitement de masse par la diethylcarbamazine, le levamisole et I'association diethylcarbamazine + levamisole. Me'decine tropicale, 39: 619-628 (1979). 42. VAN DEN BOSSCHE, H. ET AL. Mebendazole and related . Advances in pharma- cology and chemotherapy, 19: 67-127 (1982). 43. WILSON, J. F. & RAUSCH, R. L. Mebendazole and alveolar hydatid disease. Annals of tropical medicine and parasitology, 76: 165-173 (1982). 44. DENHAM, D. A. ET AL. The effects of flubendazole on Brugia pahangi. Trans- actions of the Royal Society of Tropical Medicine and Hygiene, 73: 673-676 (1979). 45. COMBESCOT, C. & DUONG, T. H. Action du fluoromebendazole (Flubendazole) sur les hel- minthiases digestives. Medicine et maladies infectieuses, 10: 735-738 (1980). 46. Azziz, M. A. ET AL. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet, 2: 171-173 (1982). 47. FUGLSANG, H. & ANDERSON, J. Effects of a single dose of metrifonate on the forest strain of Onchocerca volvulus in Cameroon. Tropenmedizin und Parasitologie, 28: 439-446 (1977). 48. KALE, 0. 0. Further trials of mebendazole and metrifonate in the treatment of onchocerciasis. Bulletin of the World Health Organization, 60: 109-113 (1982). 49. AWADZI, K. & GILLES, H. M. The chemotherapy of onchocerciasis. III. A comparative study of diethylcarbamazine (DEC) and metrifonate. Annals of tropical medicine and parasitology, 74: 199-210 (1980). 50. WOLF, H. ET AL. Analysis of enzymatically isolated adults of Onchocerca volvulus after treatment of patients with suramin or metrifonate. Tropenmedizin und Parasitologie, 31: 143-148 (1980).